cardiovascular conference: approach to a patient with cyanotic heart disease
DESCRIPTION
CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease. General Data:. Name: Baby Boy G Neonate. History of the Present Illness. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/1.jpg)
CARDIOVASCULAR CONFERENCE: APPROACH TO A PATIENT WITH CYANOTIC HEART DISEASE
![Page 2: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/2.jpg)
General Data:
Name: Baby Boy G Neonate
![Page 3: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/3.jpg)
History of the Present Illness Baby Boy Guadiz is born to 22-year
old primigravid 2nd year nursing student mother, married to a 23-year old unemployed partner. Initial pre-natal check up of the mother was at 6 month at a local health center. CBC and urinalysis results done revealed normal results.
![Page 4: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/4.jpg)
History of the Present Illness UTZ done showed Single Live
Intrauterine pregnancy, cephalic, good cardiac and somatic activity, 24-25 weeks AOG, to rule out hypoplastic Right Ventricle. For further evaluation, the mother consulted at our institution and was advised fetal 2D echo.
![Page 5: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/5.jpg)
History of the Present Illness The fetal 2D echo revealed pertinent
findings of hypoplastic Left Ventricle, hypoplastiv Mitral Valve, and a patent foramen ovale. At 26-27 weeks AOG, the mother had trichomoniasis for which she was given metronidazole tablet for 7 days. At 37-38 weeks, the mother developed UTI. Cefuroxime 500mg BID was given for 7 days that provided symptomatic relief.
![Page 6: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/6.jpg)
History of the Present Illness The mother denied any exposure to
viral exanthems and radiation. No illicit drugs and abortifacients use. She is a non-smoker; however, was a previous alcoholic beverage drinker. Hep B screening was non-reactive and OGCT was normal. No history of hypertension, allergy, thyroid disease, diabetes, asthma, or blood dyscrasia.
![Page 7: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/7.jpg)
History of the Present Illness Family history is negative for diabetes
mellitus, hypertension, and cardiovascular disease. The mother came in our institution for follow up but was 3cm dilatation, 70% effacement intact BOW, there was progression of labor alongside with spontaneous rupture of BOW. Clear, non-foul smelling amniotic fluid was observed. Repeat fetal 2D echo was not done due to lack of funds.
![Page 8: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/8.jpg)
History of the Present Illness Patient was born live, term,
singleton, male, delivered via normal spontaneous delivery, BW 2.75 kg, BL 48 cm, AS 6 and 7, MT 38-39 weeks AOG, AGA.
![Page 9: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/9.jpg)
Physical Examination on Admission: HR 134, RR 58, T 37.2˚C BW 2.75 kg, BL 48 cm, HC 33 cm, CC 31 cm,
AC 29 cm, AS 6 and 7, MT 38-39 weeks, AGA Blue, pale; some flexion of extremities, good
respiratory effort, cyanotic (-) Rash, (-) birth marks, (+) Molding, (+) caput succedaneum (-)
cephalhematoma (+) ROR OU, (-) eye discharge, normal set
ears, (-) preauricular pits, patent nares, (-) Epstein’s pearls
![Page 10: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/10.jpg)
Physical Examination on Admission: (-) Palpable neck masses, intact clavicle, no
crepitations (-) Chest deformities, symmetrical chest expansion, (-)
retractions, clear and equal breath sounds Adynamic precordium, regular heart rate and rhythm,
S1 and S2 normal, (-) murmurs Globular abdomen, (+) umbilical stump with 2 arteries
and 1 vein, (-) organomegaly, (-) palpable masses Grossly male, bilaterally descended testes, good
rugae, patent anus Femoral pulses full and equal, (-) Barlow, (-) Ortolani Straight spine, (-) sacral dimpling, (-) tuft of hair (+) Moro, grasp, rooting, plantar, and sucking reflexes
![Page 11: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/11.jpg)
APPROACH TO DIAGNOSIS OF A PATIENT PRESENTING WITH CYANOSIS AT BIRTH
![Page 12: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/12.jpg)
Indicators that heart disease may exist
Cyanosis Cardiomegaly (Radiologic or Pericardial
bulge) Pathologic heart murmur Tachypnea or overt respiratory distress
(dyspnea) Sweating especially during feeding Increased or decreased pulses Failure to thrive
![Page 13: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/13.jpg)
Classification of Congenital Heart Diseases
A) Acyanotic
B) Cyanotic
![Page 14: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/14.jpg)
Major Considerations
Is there a shunt (LR or RL) Is there obstruction to inflow or
outflow Abnormal heart valves Abnormal connections of great
vessels Combination
![Page 15: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/15.jpg)
Subgroups of Acyanotic Diseases
Shunt anomalies Valvular defects Obstructive lesions Inflow anomalies Primary myocardial diseases
![Page 16: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/16.jpg)
Shunt Anomalies
L R shunt Increased pulmonary blood flow Increased pulmonary vascular
arterial markings on chest Xray
ASD, VSD, PDA
![Page 17: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/17.jpg)
Obstructive Lesion
Discrepancy in amplitude of the peripheral pulses
Coarctation of the Aorta
![Page 18: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/18.jpg)
Inflow Anomalies
Increased pulmonary venous markings on chest Xray
No murmur
Cor Triatriatum, Pulmonary vein stenosis
![Page 19: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/19.jpg)
Valvular Defects
Stenosis or regurgitant Characteristic murmur
AS, AR, PS, PR, MS, MR, TS, TR
![Page 20: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/20.jpg)
Primary Myocardial Diseases No murmur Disparity between cardiac size and
pulmonary vascular markings
Glycogen storage disease Cardiomyopathy
![Page 21: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/21.jpg)
Hemodynamic Consequences
A) Volume (Diastolic) overload
B) Pressure (Systolic) overload
![Page 22: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/22.jpg)
ASD
Hemodynamic ConsequenceDiastolic overload of RV
![Page 23: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/23.jpg)
VSD Hemodynamic
Consequence MODERATE SIZE
Volume overload of LV
LARGE SIZE Volume overload
of LV Pressure overload
of RV
![Page 24: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/24.jpg)
Cyanotic Heart Disease
Cyanotic heart disease exist when one defect or association of defects allow the mixture of saturated and de-saturated blood to reach the systemic circulation
![Page 25: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/25.jpg)
Do you suspect that patient is Cyanotic?
When in doubtA) ClubbingB) CBCC) Hyperoxia test
![Page 26: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/26.jpg)
Hyperoxia Test
Hyperoxia test is considered positive for intracardiac shunting if PO2 < 150 mmHg (torr) after 10 minutes of 100% fiO2
![Page 27: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/27.jpg)
PVA / IVS Hemodynamic
Consequence Pressure
overload of RV
![Page 28: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/28.jpg)
PVA / VSD Hemodynamic
Consequence Pressure
overload of RV
![Page 29: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/29.jpg)
PDA Dependent Pulmonary Circulation
Pulmonary valve atresia (PVA) with intact interventricular septum
Other lesions with accompanying PVA
![Page 30: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/30.jpg)
Approach to diagnosis
A) Chest Xray Increased or decreased pulmonary vascular arterial markings
B) EKG RVH, LVH, CVH
C) Character of second heart sound
S2 single, loudS2 single, normalSplit S2
![Page 31: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/31.jpg)
CHEST X-RAY
![Page 32: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/32.jpg)
Causes of Cyanosis
Noncardiac Cardiac •Pulmonary disorders (structural abnormalities of the lung, ventilation-perfusion mismatching, congenital or acquired airway obstruction, pneumothorax, hypoventilation)•Abnormal forms of hemoglobin (methemoglobin)•Poor peripheral perfusion (sepsis, hypoglycemia, dehydration, hypoadrenalism)•primary or persistent pulmonary hypertension
Increased pulmonary vascularity•D-TGA•TAPVR without obstruction•PTA•Single ventricle•DORV w/o PS•PPHN
Decreased pulmonary vascularity•TOF•Ebstein’s anomaly•PS•PA•TA with PS•DORV with PS
![Page 33: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/33.jpg)
Pulmonary Vascular MarkingsDecreased: Cyanotic
TOF Tricuspid Atresia
Complex heart with PS PVA / IVS
![Page 34: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/34.jpg)
Second Heart Sound (S2)
Single Loud Single Normal Split S2
TGA TOF TAPVR without obstruction
Aortic / Mitral atresia
Tricuspid atresia
Truncus Arteriosus
PVA
![Page 35: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/35.jpg)
Cardiac Work-Up
A) EKGB) Chest XrayC) 2D echocardiography
(TTE, TEE, ICE, IVUS)D) Cardiac catheterizationE) CT angiography, cardiac MRI
![Page 36: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/36.jpg)
PLACE THE: ECG 2-D ECHO
![Page 37: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/37.jpg)
Modalities of Management
A) PharmacologicB) Catheter based therapyC) Surgical
![Page 38: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/38.jpg)
Pharmacologic
A) digoxin, diuretics, inotropes (pressor), vasodilators
B) Prostaglandin
![Page 39: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/39.jpg)
Catheter Based Therapy (DI KO PA ALAM ITO, EXAMPLES LANG TO)A) Balloon atrio septostomy (Rashkind)B) Balloon valvuloplastyC) Balloon angioplastyD) Delivery of occlusion devicesE) Radio frequency ablation
![Page 40: CARDIOVASCULAR CONFERENCE: Approach to a patient with cyanotic heart disease](https://reader036.vdocuments.us/reader036/viewer/2022062520/5681649f550346895dd68920/html5/thumbnails/40.jpg)
Surgical (DI KO PA ALAM ITO, EXAMPLES LANG TO)A) Shunts like Modified Blalock-TaussigB) PA bandC) Complete repairD) Glenn, FontanE) NorwoodF) Jatene, Mustard, Senning